S
Stockadora

Recent Annual Reports

Browse the latest SEC filings with AI-powered analysis. Get insights into corporate performance, financial trends, and business developments.

📊 4797 Reports
🤖 AI Analyzed
Recent
📄 Page 142 of 400
Bionano Genomics, Inc.
10-K March 23, 2026

Key Highlights

  • OGM secured a new Category I CPT code for constitutional genetic disorders and a...
  • The company sees a substantial $10.0 billion yearly market opportunity for its O...
  • Strong scientific validation continues with 450 peer-reviewed OGM publications i...
Read Analysis
🤖 AI Generated
EQUATOR Beverage Co
10-K March 23, 2026

Key Highlights

  • Achieved a significant financial turnaround in 2025, reporting a profit of $49,2...
  • Experienced impressive sales growth of 29%, reaching $4.19 million, driven by in...
  • Gross margins improved significantly to 45% in 2025, indicating better cost mana...
Read Analysis
🤖 AI Generated
TALPHERA, INC.
10-K March 23, 2026

Key Highlights

  • Niyad, a top drug candidate, received FDA Breakthrough Device Designation and ha...
  • The company strategically shifted focus to its nafamostat-based drug pipeline, i...
  • TALPHERA acquired Lowell Therapeutics, Inc. for $32.5 million, adding new produc...
Read Analysis
🤖 AI Generated
World Omni Auto Leasing LLC
10-K March 23, 2026

Key Highlights

  • World Omni Financial Corp. (Servicer) certified it met all its duties for the ye...
  • The Trust's structure includes extra protections for bond investors, such as ove...
  • The securitization process helps World Omni Financial Corp. diversify its fundin...
Read Analysis
🤖 AI Generated
Lithium Argentina AG
20-F March 23, 2026

Key Highlights

  • Cauchari-Olaroz project is now in production, producing an estimated 34,000 tonn...
  • Strategic split from Lithium Americas Newco on January 23, 2025, establishing a ...
  • Secured off-take agreements with major partners like Ganfeng Lithium Co Ltd and ...
Read Analysis
🤖 AI Generated
Arbutus Biopharma Corp
10-K March 23, 2026

Key Highlights

  • Major cash infusion from $950M Moderna settlement, with Arbutus's share estimate...
  • Potential for an additional $1.3B from Moderna if a specific patent appeal is wo...
  • Favorable court ruling in Pfizer/BioNTech patent lawsuit strengthens their case ...
Read Analysis
🤖 AI Generated
Charging Robotics Inc.
10-K March 23, 2026

Key Highlights

  • Acquired a majority stake in Revoltz Ltd., expanding into the high-growth micro-...
  • Secured initial orders for 15 wireless EV charging systems for Automatic Parking...
  • Holds valuable intellectual property, including US patents and global applicatio...
Read Analysis
🤖 AI Generated
Brazil Potash Corp.
20-F March 23, 2026

Key Highlights

  • Developing the strategic Autazes Potash Project in Brazil, targeting about A mil...
  • Pre-Feasibility Study (PFS) shows strong project finances: about $X billion Afte...
  • Listed on NYSE American ('GRO') and filed for Canadian IPO, enhancing access to ...
Read Analysis
🤖 AI Generated
BioLineRx Ltd.
20-F March 23, 2026

Key Highlights

  • APHEXDA® (motixafortide) received FDA approval, marking BioLineRx's first commer...
  • Strategic licensing deals for APHEXDA® significantly reduced annual losses and r...
  • Annual losses dramatically decreased from $60.6 million in 2023 to $2.0 million ...
Read Analysis
🤖 AI Generated
Permianville Royalty Trust
10-K March 23, 2026

Key Highlights

  • Operates as a Royalty Trust, receiving 80% of net profits from oil and gas produ...
  • Actively building a cash reserve, reaching $1,441,386 by Dec 31, 2025, towards a...
  • Benefits from a $1.2 million letter of credit from COERT, providing financial pr...
Read Analysis
🤖 AI Generated
Avalo Therapeutics, Inc.
10-K March 23, 2026

Key Highlights

  • Secured full global rights to abdakibart (AVTX-009), a promising late-stage drug...
  • Completed patient enrollment for the AVTX-009 Phase 2 LOTUS trial in October 202...
  • Filed new patents for AVTX-009, potentially extending market protection until 20...
Read Analysis
🤖 AI Generated
Chemomab Therapeutics Ltd.
20-F March 23, 2026

Key Highlights

  • Advancing nebokitug (CM-101) in critical Phase 2 trials for primary sclerosing c...
  • Completed multiple early-stage clinical trials (Phase 1a, 1b, 2a, and explorator...
  • Focused on a targeted approach to inflammation and fibrosis by blocking CCL24 si...
Read Analysis
🤖 AI Generated

Stay Informed with AI Analysis

Get comprehensive insights from annual reports with our AI-powered analysis. Track corporate performance, financial trends, and strategic developments.

Back to Homepage